.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

New Directions in CLL

EP. 1: Dr. Ma on Utilizing Zanabrutinib in CLL

May 10th 2022

Shuo Ma, MD, PhD, discusses the utilization of zanubrutinib in chronic lymphocytic leukemia.

EP. 2: Dr. Heyman on the ALPINE Trial in CLL

May 10th 2022

Benjamin Heyman, MD, discusses the phase 3 ALPINE trial in chronic lymphocytic leukemia.

EP. 3: Dr. Furman on Current Treatment Options in CLL

May 10th 2022

Richard R. Furman, MD, discusses current treatment options in chronic lymphocytic leukemia.

EP. 4: New Directions in Chronic Lymphocytic Leukemia

June 9th 2022

This publication highlights expert perspectives on the current therapeutic landscape in chronic lymphocytic leukemia with emphasis on factors affecting treatment selection including novel regimens, combination therapies, and ongoing clinical trials.